October 19, 2022
VIA EDGAR
Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549-7010
USA
| Re: | Aptose Biosciences Inc. |
| Registration Statement on Form S-3 | |
| Filed October 11, 2022 | |
| File No. 333- 267801 |
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Aptose Biosciences Inc. (the “Company”) hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement (the “Registration Statement”) to October 21, 2022 at 5:00 p.m. (Eastern) or as soon thereafter as is practicable.
The Company also requests the Commission confirm the effective date and time of the Registration Statement in writing.
| APTOSE BIOSCIENCES INC. | |||
| By: | /s/ Fletcher Payne | ||
| Name: | Fletcher Payne | ||
| Title | Senior Vice President & Chief Financial Officer | ||